- Home
- ZENV vs SERA Comparison
ZENV vs SERA Comparison
Compare ZENV & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- SERA
- Stock Information
- Founded
- ZENV 2005
- SERA 2008
- Country
- ZENV Brazil
- SERA United States
- Employees
- ZENV N/A
- SERA N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- SERA Precision Instruments
- Sector
- ZENV Technology
- SERA Health Care
- Exchange
- ZENV Nasdaq
- SERA Nasdaq
- Market Cap
- ZENV 79.7M
- SERA 90.6M
- IPO Year
- ZENV 2021
- SERA 2021
- Fundamental
- Price
- ZENV $1.43
- SERA $3.15
- Analyst Decision
- ZENV
- SERA
- Analyst Count
- ZENV 0
- SERA 0
- Target Price
- ZENV N/A
- SERA N/A
- AVG Volume (30 Days)
- ZENV 104.7K
- SERA 57.2K
- Earning Date
- ZENV 11-17-2025
- SERA 11-05-2025
- Dividend Yield
- ZENV N/A
- SERA N/A
- EPS Growth
- ZENV N/A
- SERA N/A
- EPS
- ZENV N/A
- SERA N/A
- Revenue
- ZENV $201,426,369.00
- SERA $108,000.00
- Revenue This Year
- ZENV $6.49
- SERA $217.92
- Revenue Next Year
- ZENV $3.82
- SERA $479.25
- P/E Ratio
- ZENV N/A
- SERA N/A
- Revenue Growth
- ZENV 24.80
- SERA 0.94
- 52 Week Low
- ZENV $1.02
- SERA $1.37
- 52 Week High
- ZENV $3.03
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- ZENV 54.00
- SERA N/A
- Support Level
- ZENV $1.26
- SERA N/A
- Resistance Level
- ZENV $1.48
- SERA N/A
- Average True Range (ATR)
- ZENV 0.08
- SERA 0.00
- MACD
- ZENV 0.02
- SERA 0.00
- Stochastic Oscillator
- ZENV 90.91
- SERA 0.00
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.